What’s New

What's New

Testosterone Therapy May Lower Risk of CV Events in Older Men




Rigorous studies have not linked testosterone replacement therapy to heart attack or stroke, and the decision to prescribe testosterone replacement therapy should be based on a full diagnostic work-up – not the underlying cause of hypogonadism, according to a new position statement from the American Association of Clinical Endocrinologist.

The statement challenges several aspects of a recent Food and Drug Administration safety announcement warning about “possible” increased risks of heart attack and stroke with testosterone replacement therapy (TRT) and approving its use only for testicular, pituitary, or brain disorders that cause low testosterone, not for age-associated hypogonadism.

In fact, AACE said, randomized controlled trials have lacked the power to assess whether TRT increases the chances of cardiovascular events or death. Data linking TRT to cardiovascular problems come from a few retrospective studies, the “major flaws” of which limit their ability to assess risk.

"Large-scale prospective randomized controlled trials on testosterone therapy, focusing on cardiovascular benefits and risks, are clearly needed. As with therapeutics in general, common sense, experience, and an individualized approach are recommended,” according to the statement (Endocr Pract. 2015;21:1066-73).

The benefits and risks of TRT in age-associated hypogonadism remain uncertain, according to both the FDA and AACE. Until better studies are available, AACE recommends that clinicians consider TRT for men with signs and symptoms that are consistent with hypogonadism, regardless of cause, and who have at least two “unequivocally low” testosterone levels in samples drawn before 10 a.m.

Clinicians also should educated patients about the possible cardiovascular risks of TRT, should be “extra cautious” when considering TRT, for symptomatic elderly men with low testosterone levels, and should avoid TRT entirely in frail elderly men “until better outcome data are available,” AACE also recommended. Furthermore, clinicians should avoid TRT for patients with uncontrolled or poorly controlled heart failure, a history of heart attack or cerebrovascular accident within the past 6 months, an individual or family history of a procoagulant state, or an individual history of thromboembolism, AACE stated.

Although TRT can improve some cardiovascular risk factors by promoting muscle gain and fat loss, decreasing insulin resistance, and potentially reversing metabolic syndrome, it remains unclear whether low testosterone is a marker of cardiovascular illness or a casual factor, AACE noted. Replacement therapy is most likely to benefit men with very low testosterone levels, not those whose levels are just below normal, according to the AACE.

The American Urological Association has echoed several recommendations from AACE, emphasizing in its own statement that “testosterone therapy in the absence of hypogonadism is inappropriate” and calling for more federal and industry funding for studies of the indications, benefits, and risks of approved treatments for hypogonadism as well as studies of new potential therapies. “Current evidence does not provide any definitive on prostate cancer and cardiovascular disease, and patients should be so informed,” noted the statement from the AUA, which was last updated in August 2015.

The AACE Reproductive Endocrinology Scientific Committee listed the following disclosures: First author Dr. Neil Goodman reported serving on the AbbVie speaker bureau for AndroGel, and senior author Dr. Glenn Cunningham reported receiving research support from Abbvie, having served on advisory panels for Abbvie; Apricus, Clarus Therapeutics, Endo Pharma, and Lilly; and having consulted for Clarus Therapeutics, Endo Pharma, Ferring, Purdue Pharma, and Repros Therapeutics. Two other coauthors declared financial relationships with Abbvie, GlaxoSmithKline, Merck, Sanofi-Aventies, and a number of other pharmaceutical companies. The other two coauthors declared no competing interests.

-internalmedicinenews.com October 15, 2015

Journal of Sexual Medicine Study

The Journal of Sexual Medicine published a study in 199 diabetic males and reported a significant improvement in all areas of sexual functioning , mood and quality of life in the men using testosterone therapy vs. placebo.

Consistently well documented benefits of TRT include improved sexual functioning, decreased fat and increased lean body mass, increases in muscle mass and strength, as well as a reduction in several cardiometabolic risk factors such as insulin resistance, waist circumference and fasting blood glucose.

Testosterone and Heart Attacks

LawyersandSettlements.com Interviews Two Experts Regarding Testosterone and Heart Attack as the Debate Heats Up. Read more here


Get Tested

It's quick, easy, and there's never a wait at our local clinics. Schedule an appointment now.